Insight

Howard McLeod Highlighted The Results of the Phase II Randomized LEANOX Trial

Howard McLeod/LinkedIn

Aug 10, 2025, 05:10

Howard McLeod Highlighted The Results of the Phase II Randomized LEANOX Trial

Howard McLeod, Center Director at Center for Precision Medicine & Functional Genomics, shared a post on LinkedIn:

“Details matter in cancer therapy! Use of lean body mass, rather then total body mass, for Oxalaplatin chemotherapy resulted in similar relapse free survival, but much less peripheral neuropathy! Precision oncology doesn’t just mean fancy genomics or such.”

Title: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

Authors: Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi, Côme Lepage, Raphael Tetreau, Pierre Senesse

Read the Full Article.

Howard McLeod

Read more posts on Colon Cancer.

cancer chemotherapy Chloé Janiszewski Côme Lepage Eric Assenat Faiza Khemissa Akouz Hervé Perrier Howard McLeod LEANOX Trial Marie-Pierre Galais Meher Ben Abdelghani OncoDaily Oncology Pierre Senesse Raphael Tetreau Romain Desgrippes Sophie Gourgou Thibault Mazard Yves Rinaldi

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen